# US 2024/0003869 A1 · Plasmonic cell mass accumulation profiling platform for determining therapeutic response of cancer cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003869 A1
- Document ID: US20240003869A1
- Status: Published application
- Kind: A1
- Application number: 18/255,377
- Filed: 2021-11-10
- Published: 2024-01-04
- Earliest claimed: 2020-12-02
- Assignees: Izmir Biyotip Ve Genom Merkezi
- Applicants: Izmir Biyotip Ve Genom Merkezi
- Inventors: Arif Engin CETIN
- Web page: https://patentgrep.com/patent/US20240003869A1

## CPC

- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 21/554: {detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A plasmonic-based biosensor platform that determines the biophysical properties of cells, the changes within, and their therapeutic behavior upon the molecules that cause these changes in an ex vivo and label-free manner is provided. The plasmonic-based biosensor platform includes a plasmonic chip, a light source, an inverted microscope, an incubator case, an optical read-out device, and a graphical user interface. The biosensor platform of the invention could determine the therapeutic susceptibility of cancer cells to cancer drugs in a label-free manner.

## Claims

### Claim 1

A plasmonic-based biosensor platform for detecting biophysical properties of cells and changes within, as well as a therapeutic response of the cells against molecules causing the changes in a label-free and ex vivo fashion, comprising:
a plasmonic chip consisting of a periodic nanohole array fabricated on a nm-thick metal film and a surface where the cells to be examined are seeded,
a light source illuminating the plasmonic chip,
an inverted microscope used to illuminate the plasmonic chip to collect a light transmitted from the plasmonic chip and to send the light to an optical read-out device,
an incubator case providing incubator conditions for a cell culture and integrated to the inverted microscope,
the optical read-out device measuring a transmission response of the plasmonic chip and integrated to the inverted microscope,
a graphical user interface with algorithms controlling the optical read-out device and converting outputs of the optical read-out device into meaningful MAR information.

### Claim 2 (depends on 1)

The plasmonic-based biosensor platform according to claim 1, wherein the optical read-out device is a spectrometer coupled to the inverted microscope with a fiber coupling-optical setup.

### Claim 3 (depends on 1)

The plasmonic-based biosensor platform according to claim 1, wherein the optical read-out device is a camera.

### Claim 4 (depends on 3)

The plasmonic-based biosensor platform according to claim 3, wherein the optical read-out device comprises a liquid crystal (LC) filter assembled on the light source when the camera is present.

### Claim 5 (depends on 4)

The plasmonic-based biosensor platform according to claim 4, wherein the LC filter is in a bandwidth range of 0-5 nm.

### Claim 6 (depends on 1)

The plasmonic-based biosensor platform according to claim 1, wherein the plasmonic-based biosensor platform has an ability to determine a cell mass and to detect real-time changes within.

### Claim 7 (depends on 1)

The plasmonic-based biosensor platform according to claim 1, wherein the plasmonic-based biosensor platform has an ability to determine a mass accumulation behavior and the therapeutic response of single cells or cell populations.

### Claim 8 (depends on 7)

The plasmonic-based biosensor platform according to claim 7, wherein the plasmonic-based biosensor platform has an ability to determine therapeutic effects of cancer drugs on cancer cells in a real-time, label-free and ex vivo fashion.

### Claim 9 (depends on 1)

The plasmonic-based biosensor platform according to claim 1, wherein a sensitivity of the plasmonic-based biosensor platform is within a range of 0-1 picogram/hour.

### Claim 10 (depends on 1)

A device comprising the plasmonic-based biosensor platform according to claim 1.

### Claim 11 (depends on 1)

A method of detecting the biophysical properties of the cells, biophysical changes of the cells, and a therapeutic behavior of the cells against molecules causing the biophysical changes in the label-free and ex vivo fashion using the plasmonic-based biosensor platform according to claim 1, comprising a determination of changes in a mass of cells seeded on the surface of the plasmonic chip, wherein single cells are positioned in each sensor region, with a use of spectral changes within the transmission response of the periodic nanohole array or light intensity changes in a single cell level.

### Claim 12 (depends on 1)

A method of determining the biophysical properties, the changes within and a therapeutic behavior of the cells against the molecules causing changes in the label-free and ex vivo fashion with the plasmonic-based biosensor platform according to claim 1, comprising steps of:
seeding the cells to be examined on the surface of the plasmonic chip consisting of the periodic nanohole array fabricated on the nm-thick metal film,
placing the plasmonic chip with the surface where the cells are seeded on in a sample holder containing a cell medium,
illuminating the plasmonic chip with the light source in a visible light spectrum,
filtering some light coming into the plasmonic chip by the periodic nanohole array, and allowing a filtered light to pass in a spectral window of 50 nm within the visible light spectrum,
collecting the light transmitted from the plasmonic chip with an objective lens of the inverted microscope,
determining a of the cells by measuring a mass accumulation behavior of single cells on the surface of the plasmonic chip with the optical read-out device consecutively or simultaneously.
